Number of participants with serious Adverse Events;Number of participants with solicited local injection site reactions;Number of participants with solicited systemic reactions starting within 7 days of administration of the vaccine;Number of participants with unsolicited adverse events;Number of participants with unsolicited adverse reactions (ARs) throughout the study;The titer of serum neutralizing antibodies 2 weeks after the second vaccination in the SARS-CoV-2 pseudovirus-based neutralization assay;The titer of vaccine-induced serum IgG binding antibody responses to the SARS-CoV-2 S glycoprotein 2 weeks after the first and second vaccinations

Number of participants with serious Adverse Events;Number of participants with solicited local injection site reactions;Number of participants with solicited systemic reactions starting within 7 days of administration of the vaccine;Number of participants with unsolicited adverse events;Number of participants with unsolicited adverse reactions (ARs) throughout the study;The titer of serum neutralizing antibodies 2 weeks after the second vaccination in the SARS-CoV-2 pseudovirus-based neutralization assay;The titer of vaccine-induced serum IgG binding antibody responses to the SARS-CoV-2 S glycoprotein 2 weeks after the first and second vaccinations